Perelman School of Medicine

Targeting a viral vulnerability to treat disease

Robert Ricciardi company ViRAZE utilizes interdisciplinary approaches to drug discovery. Its first target is molluscum contagiosum, a disease that targets children and immune-compromised adults with no current FDA-approved therapy.

Finding patterns in a class of neurological disorders

Research from Penn Engineering and the Perelman School of Medicine has found that the shared pattern is misfolded in Fragile X Syndrome, a member of the class of disorders that also includes ALS and Huntington’s disease

Stigmatizing views and myths about psoriasis are pervasive

New multidisciplinary research involving both psychologists and dermatologists from the Perelman School of Medicine is the first to examine how common this stigma may be among the general population of the United States.

Mary Walton, Director of the Family Caregiver Center

An oasis of compassion

Since 2015, the Hospital of the University of Pennsylvania has supported the Family Caregiver Center, a three-room space that serves an array of needs, from resources to relaxation, for caregivers—one of only a few in the United States.

CAR T cell therapy receives approval for use across European Union

The European Commission has approved a personalized cellular therapy developed at the Abramson Cancer Center, making it the first CAR T cell therapy permitted for use in the European Union in two distinct indications.

New insights into malaria culprit

New insights from the Perelman School of Medicine on the origins of deadly infectious diseases are vital to understanding the emergence of human pathogens, and may even lead to eradicating malaria.

A promising candidate for a universal flu vaccine

A flu vaccine that targets a deeper level of the virus itself may be the key to a universal flu vaccine that is more effective at protecting humans from any strain of flu each season.

Knockdown and replace: A gene therapy twofer to treat blindness

More than 150 different mutations in the light-sensing molecule rhodopsin can cause retinitis pigmentosa, characterized by a progressive loss of night and peripheral vision, and a team of researchers have developed a treatment for the condition. Successful results in dogs set the stage for testing in humans.

‘Alarming’ diabetes epidemic in Guatemala tied to aging, not obesity

A new study by Penn Center for Global Health, published in PLOS One, finds that 25 percent of the large indigenous population in Guatemala has either type 2 diabetes or pre-diabetes.

Penn Medicine’s Carl June receives 2018 Albany Prize

Carl June, a gene therapy pioneer at the Abramson Cancer Center, will receive the 2018 Albany Medical Center Prize in Medicine and Biomedical Research.

Filters